Analyst Price Targets — CARM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 11, 2024 6:33 am | Justin Zelin | BTIG | $6.00 | $1.91 | StreetInsider | BTIG Starts Carisma Therapeutics Inc (CARM) at Buy |
Latest News for CARM
Carisma Therapeutics (NASDAQ: CARM - Get Free Report) and Protalex (OTCMKTS:PRTX - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership. Insider and Institutional Ownership 44.3% of Carisma Therapeutics shares
PARIS--(BUSINESS WIRE)--Regulatory News: Carmila (Paris:CARM): Three growth engines: NRI up 8.8% to €403.1 million Organic growth: adding 3.5% to net rental income, outpacing indexation by 110 basis points. Investment growth: adding 5.3% to net rental income; successful integration of Galimmo Innovation growth: recurring earnings contribution of €27 million, growing by 14% Operational excellence confirmed, all KPIs…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CARM.
U.S. House Trading
No House trades found for CARM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.